October 7, 2020 -- Eli Lilly submitted an emergency use authorization (EUA) request from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 monoclonal antibodies (mAbs).
Data show that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes, according to the company. It plans to make these therapies broadly available to patients.
Lilly anticipates it could supply up to 1 million doses of 700 mg of LY-CoV555 monotherapy in the last quarter of 2020, with 100,000 available in October. The company anticipates it will have 50,000 doses of its combination therapy available in the fourth quarter of 2020. The supply of combination therapy will increase substantially in the beginning of 2021, according to the firm.